Q-omics provides the consensus-scored SCN3A profile across patient tissues and cancer cell-line models. SCN3A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SCN3A is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SCN3A RNA expression shows 17,099 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UVM, COAD, and PCPG as cancer lineages where SCN3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN3A survival associations across molecular data types. SCN3A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN3A RNA expression–survival associations across cancer types. High SCN3A expression shows unfavorable associations in UVM, but favorable associations in LIHC, HNSC, BRCA, LGG and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for SCN3A RNA expression.
This table summarizes SCN3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SCN3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN3A shows lower tumor expression in COAD, THCA, KIRC, KICH, BRCA and KIRP. The COAD box plot shows higher SCN3A RNA expression in normal versus tumor tissue (log2 FC = −0.586, t-test p < 0.001).
This table shows molecular features associated with SCN3A in patient tissues and cancer cell lines. In patient samples, SCN3A shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
